(Q45985026)

English

Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.

scientific article published on 21 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

1 reference

based on heuristic

inferred from title

author name string

Ellen J Scherl

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

Ronald Pruitt

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

Glenn L Gordon

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

Mark Lamet

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

Audrey Shaw

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

Shirley Huang

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

Shadreck Mareya

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

William P Forbes

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

language of work or name

0 references

publication date

21 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

104

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

1452-1459

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

https://scigraph.springernature.com/pub.10.1038/ajg.2009.83

0 references

Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Guidelines for the management of inflammatory bowel disease in adults

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Review article: inflammatory bowel disease--empowering the patient and improving outcome

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.83

21 January 2018

Identifiers

10.1038/AJG.2009.83

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491859

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45985026&oldid=1202195587"